Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 433

1.

Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.

Gorai I, Hattori S, Tanaka Y, Iwaoki Y.

J Bone Miner Metab. 2012 May;30(3):349-58. doi: 10.1007/s00774-011-0325-1. Epub 2011 Dec 2.

PMID:
22130786
[PubMed - indexed for MEDLINE]
2.

Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.

Gorai I, Tanaka Y, Hattori S, Iwaoki Y.

J Bone Miner Metab. 2010 Mar;28(2):176-84. doi: 10.1007/s00774-009-0112-4. Epub 2009 Aug 6.

PMID:
19657590
[PubMed - indexed for MEDLINE]
3.

A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.

Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T.

J Clin Endocrinol Metab. 2001 Mar;86(3):1212-21. Erratum in: J Clin Endocrinol Metab 2001 Jul;86(7):3008.

PMID:
11238511
[PubMed - indexed for MEDLINE]
4.

Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.

Tanaka M, Itoh K, Matsushita K, Matsushita K, Moriishi M, Kawanishi H, Fukagawa M.

Ther Apher Dial. 2011 Jun;15 Suppl 1:62-6. doi: 10.1111/j.1744-9987.2011.00929.x.

PMID:
21595855
[PubMed - indexed for MEDLINE]
6.

Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.

Nuti R, Bianchi G, Brandi ML, Caudarella R, D'Erasmo E, Fiore C, Isaia GC, Luisetto G, Muratore M, Oriente P, Ortolani S.

Rheumatol Int. 2006 Mar;26(5):445-53. Epub 2005 Nov 10.

PMID:
16283320
[PubMed - indexed for MEDLINE]
7.

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.

J Bone Miner Res. 2005 Nov;20(11):1905-11. Epub 2005 Jul 18.

PMID:
16234962
[PubMed - indexed for MEDLINE]
8.

Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.

Coin A, Veronese N, Bolzetta F, De Rui M, Manzato E, Sergi G.

Panminerva Med. 2012 Dec;54(4):277-82.

PMID:
23123579
[PubMed - indexed for MEDLINE]
9.

[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.

Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):269-73. Chinese.

PMID:
15059505
[PubMed - indexed for MEDLINE]
10.

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Ettinger B, San Martin J, Crans G, Pavo I.

J Bone Miner Res. 2004 May;19(5):745-51. Epub 2004 Jan 19.

PMID:
15068497
[PubMed - indexed for MEDLINE]
11.
12.

Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.

Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.

Osteoporos Int. 2003 Sep;14(9):741-9. Epub 2003 Jun 19.

PMID:
12827224
[PubMed - indexed for MEDLINE]
13.
14.

Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.

Kendler DL, Palacios S, Cox DA, Stock J, Alam J, Dowsett SA, Zanchetta J.

Osteoporos Int. 2012 Mar;23(3):1091-101. doi: 10.1007/s00198-011-1587-0. Epub 2011 Mar 4.

PMID:
21374068
[PubMed - indexed for MEDLINE]
15.

Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.

Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW.

J Rheumatol. 2007 May;34(5):1051-7. Epub 2007 Apr 1.

PMID:
17407214
[PubMed - indexed for MEDLINE]
16.
17.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.

Chin Med J (Engl). 2004 Jul;117(7):1029-35.

PMID:
15265377
[PubMed - indexed for MEDLINE]
Free Article
18.

Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.

Dane C, Dane B, Cetin A, Erginbas M.

Gynecol Endocrinol. 2007 Jul;23(7):398-403.

PMID:
17701771
[PubMed - indexed for MEDLINE]
19.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

PMID:
18088161
[PubMed - indexed for MEDLINE]
Free Article
20.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

PMID:
11889149
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk